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Abstract
Background and purpose: To investigate toxicity and efficacy in high-risk malignant salivary gland tumors (MSGT)
of the head and neck. Local control in R2-resected adenoid cystic carcinoma was already improved with a
combination of IMRT and carbon ion boost at only mild side-effects, hence this treatment was also offered to
patients with MSGT and microscopic residual disease (R1) or perineural spread (Pn+).
Methods: From November 2009, all patients with MSGT treated with carbon ion therapy were evaluated. Acute
side effects were scored according to CTCAE v.4.03. Tumor response was assessed according to RECIST where
applicable.
Results: 103 patients were treated from 11/2009 to 03/2011, median follow-up is 6 months. 60 pts received
treatment following R2 resections or as definitive radiation, 43 patients received adjuvant radiation for R1 and/or
Pn+. 16 patients received carbon ion treatment for re-irradiation. Median total dose was 73.2 GyE (23.9 GyE carbon
ions + 49,9 Gy IMRT) for primary treatment and 44.9 GyE carbon ions for re-irradiation. All treatments were
completed as planned and generally well tolerated with no > CTC°III toxicity. Rates of CTC°III toxicity (mucositis and
dysphagia) were 8.7% with side-effects almost completely resolved at first follow-up.
47 patients showed good treatment responses (CR/PR) according to RECIST.
Conclusion: Acute toxicity remains low in IMRT with carbon ion boost also in R1-resected patients and patients
undergoing re-irradiation. R2-resected patients showed high rates of treatment response, though follow-up is too
short to assess long-term disease control.
Introduction
Malignant salivary gland tumors (MSGT) are rare and
account for about 3-5% of head and neck cancers. They
include a heterogeneous group of various histological
subtypes with high-grade tumors such as mucoepider-
moid carcinoma and adenoid cystic carcinoma (ACC)
[1]. MSGTs are generally characterized by a rather slow
pattern of growth, perineural spread and high propensity
for hematogenous metastases, therefore outcome is still
hampered by the incidence of distant metastases. Stan-
dard therapy of localized high-grade MSGT consists of
complete surgical resection and adjuvant radiation in
high-risk situations (R+ or close margin, perineural
spread, large tumors (T3/4), or nodal metastases) [2-4].
Radiation doses of > 60 Gy or even 66 Gy are recom-
mended to achieve local control [5-7].
Local control in MSGT was significantly improved by
high-precision radiotherapy techniques, dose-escalation
and high-LET radiation [8-12].
Intensity-modulated radiation therapy (IMRT) as well
as fractionated stereotactic RT could already improve
local control as compared to conventional RT techni-
ques achieving 3-year PFS rates of 38% even in large
ACCs [13].
The highest local control rates at 75 - 100% [10,12]
are achieved by neutron radiation albeit at the cost of
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any medium, provided the original work is properly cited.significant late toxicity. Heavy ion therapy using carbon
ions however, showed a mild toxicity profile, no CTC°III
late toxicities and very few °III acute reactions were
observed [11]. Proton radiotherapy yielded an overall
local control of 93% at 5 years; however, the authors
noted several °III as well as one °V late toxicity (tem-
poral lobe necrosis) [14]. A retrospective analysis of
patients treated with neutrons reported slightly disap-
pointing local control rates of 57% at 5 years accompa-
nied with significant late toxicity (14% > CTC °III) [10].
IMRT plus carbon ion boost for ACC showed very
favorable results without the dreaded late toxicity result-
ing in local control rates of 78% at 4 years [9]. These
results in turn led to the acceptance of this regimen as
the standard treatment for ACC in Germany. A recent
update of patients with ACC treated with this regimen
between 1997 and 2008 confirmed initial results with
consistently low treatment-related side effects [9,15,16].
Charged-particle therapy promises improved results
for all types of malignant salivary gland cancers. We
would like to report early toxicity in a patient cohort
including various R1-resected and re-irradiated MSGT
of the head and neck.
Patients and methods
103 patients were treated with raster-scanned carbon
ion therapy from November 2009 to March 2011. Toxi-
city was assessed at completion of treatment and on
each follow-up visit. Treatment response was evaluated
according to RECIST based on contrast-enhanced MRI-
scans where applicable.
Patients
Patients with histologically confirmed or surgically
removed malignant tumors of the salivary glands (head
and neck) were offered combined IMRT plus C12-boost
in cases where tumors were either surgically inoperable
or partially (R2) resected. In contrast to our initial
experience [9], also patients with microscopic residues
(R1) or perineural invasion (Pn+) were offered the com-
bination regimen. Prior RT was not an exclusion criter-
ion if another course of radiation therapy was justifiable.
Radiotherapy
Immobilization/planning examinations
Patients were immobilized with scotch cast or thermo-
plastic head masks with shoulder fixation. Planning
examinations consisted of CT and contrast-enhanced
MRI for 3D image correlation.
Target volumes/dose prescription
Primary treatment CTV1 (carbon ion boost) includes
the macroscopic tumor/prior tumor bed, CTV 2 typical
pathways of spread/ipsilateral nodal levels (II/III),
further levels are included as indicated details of target
volume definition are described in our current standard
protocol [17].
We prescribed a dose of 24 GyE carbon ions to the
CTV1 (coverage: 95% prescription isodose). CTV2
receives 50 Gy IMRT (coverage > 90% of prescription
isodose).
Re-irradiation Patients undergoing re-irradiation
receive carbon ion therapy alone; CTV1 is limited to the
visible tumor only. Doses are prescribed highly individu-
ally depending on prior RT and interval between the
two treatments.
Treatment and patient position control
Carbon ions Carbon ion therapy is given in active beam
application in the raster-scanning method [18] at the
Heidelberg Ion Beam Therapy Centre (HIT). Inverse
treatment planning is carried out on a dedicated plan-
ning system (Siemens TPS
®) including biological RT
optimization tools. Intensity-modulated particle therapy
(IMPT) and single-beam optimization (SBO) techniques
are used for plan generation in MSGTs.
Treatment is given at 3 GyE per fraction (5 x/week),
daily image guidance consists of orthogonal x-rays in
treatment position. An automatic 2D-3D pre-match is
carried out (Siemens syngo PT treatment) and verified
and manually adjusted online by the radiotherapist
based on bony anatomy. Shifts were always corrected
using a robotic table in six degrees of freedom.
IMRT IMRT is given in 25 fractions (5 x/week) after
inverse planning with the optimization tool KonRad
MRC
® (Siemens OCS) on a 6 MV linear accelerator in
step-and-shoot technique or on a 6 MV tomotherapy unit.
Regular image guidance is carried out as MV cone-
beam CT or MV portal images. Total doses include
doses by daily image guidance with MV CT.
Treatment schedule/follow-up
Most patients received upfront carbon ion boost fol-
lowed by IMRT corresponding to a total dose of
approximately 74 GyE (total treatment duration:
approximately 7 weeks).
First follow-up including fibreoptic examination and
MRI is carried out 6 weeks post completion of RT.
Further MRI controls follow 3, 6, and 12 months there-
after, in 6 monthly intervals until 2 years post RT, then
in yearly intervals.
Analysis
Evaluation of toxicity was carried out according to NCI
CTCAE v.4.03, treatment was evaluated using the
RECIST-criteria if applicable (R2-resected or inoperable
tumors) [19].
Results
Treatment has been completed in 103 patients. Median
age in our cohort is 56 years, median follow-up 6
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able in 90 patients. Two patients from abroad are lost to
follow-up.
Sixty patients had a visible residual tumour or had not
undergone prior surgery (group 1), 43 patients had
undergone R+ resections and/or showed extensive peri-
neural spread (Pn+) (group 2). Eight out of 43 patients
(group 1) and 26/60 patients (group 2) were treated for
local relapse following initial surgery. Eighty-seven
patients received treatment as part of their primary ther-
apy. Sixteen patients received carbon ion therapy as re-
irradiation.
The majority of patients was treated for ACC and
advanced tumor stages (table 1).
All except 3 patients received radiation only, one
patient with extensive ACC received cetuximab weekly
in addition, two patients with squamous cell carcinoma
cisplatin 40 mg/m
2 body surface weekly throughout
therapy (1 patient as primary therapy, 1 patient for re-
irradiation).
Primary treatment
Median target volumes (n = 87 pts) were 368 ml (IMRT;
CTV2) and 128.6 ml (carbon ion boost; CTV1), median
total dose was 73.2 Gy. Ten patients with tumors close
to or crossing midline received bilateral cervical irradia-
tion, for three patients with positive cervical lymph
nodes and perinodal infiltration, our standard dose pre-
scription was changed to 54 - 56 Gy to the CTV2 and
18 GyE C12.
Seventeen carbon ion plans needed to be optimized as
IMPT, carbon ion treatment was mostly applied over 2
non-coplanar beams (table 2).
Re-irradiation
Sixteen patients received carbon ion therapy for re-irra-
diation of recurrent disease at the former field edge (2
pts), within the dose gradient to the optic nerve (2 pts),
and in-field (12 pts). Median interval between the two
RT courses was 66 months, median prior radiation dose
70 Gy. Six patients had initially received 72 GyE as com-
bined treatment with carbon ion boost. Median re-treat-
ment dose was 44.9 GyE (table 2).
One patient had initially received electrons to a small
parotid field > 20 years ago, therefore this patient also
received the standard IMRT + C12-boost concept
despite prior RT (table 2). Dose prescription for re-irra-
diation was highly individual prior dose and respecting
the patients’ preferences after detailed discussion of
risks and benefits.
Treatment tolerance/toxicity
Treatment was well tolerated despite comparatively long
treatment times per session (set-up, position verification,
treatment for carbon ions approx. 45 min). There was
no treatment break in any patient except one, a lady
with Miur-Torre syndrome showing pronounced swel-
ling of the irradiated area (floor of mouth/pharynx)
necessitating elective tracheal tube insertion and treat-
ment interruption for 3 fractions.
Treatment-related acute effects as assessed at comple-
tion of the radiation therapy course were generally mild
with mucositis CTC °III occurring in 9/103 pts (8.7%);
despite extensive treatment fields, no > grade I xerosto-
mia was found. Seventy-two patients (69.9%) developed
changes up to complete loss of taste gradually resolving
until the first follow-up. Twenty-one patients (20.4%)
developed middle ear effusions/otitis requiring tympa-
nostomy, 11 pts (10.7%) otitis externa. Seventeen
patients had a facial nerve palsy due to extensive surgi-
cal procedures or tumor compression, 3 patients showed
improvement of cranial nerve palsies (palsy of the IIIrd,
Vth, VIth cranial nerv) during the course of radiother-
apy completely resolving at first follow-up in 2 patients.
We observed radiation-induced erythema in 86 patients,
(62 pts °II, 25 pts °I), one of them CTC°III, small dry
epitheliolyses were seen in 20 patients (19.4%) mostly
retro-/infraauricular area. Dysphagia of some degree was
observed in about half of the patients, 3 patients were
feeding tube (PEG) dependent prior to RT, 6 patients
became PEG-dependent during therapy (dysphagia °III:
5.8%). Radiation-induced side effects (loss of appetite/
taste, dysphagia) led to weight loss in 44 patients [2 - 11
kg] due to the complete loss of taste (table 3).
Follow-up
Acute toxicity rapidly resolved in most patients, at first
follow-up, 12 patients (11.7%) still complained of some
difficulty swallowing (°I), 3 (2.9%) reported changes in
their diet (°II) while one patient was still dependent on
the feeding tube due to dental problems.
Xerostomia °I was reported by 41 patients (39.8%)
with symptoms gradually resolving. No skin reactions
apart from one case erythema °I and hyperpigmentation
°I (1 pt: 1.0%) could be observed (table 3). One patient
receiving re-irradiation developed an asymptomatic cys-
tic necrosis of the intracranial tumor part. He is under
close clinical and diagnostic follow-up.
Outcome
To date, only one patient receiving adjuvant radiation
for R1 resection for ACC developed an in-field recur-
rence. This patient rapidly developed distant metastases
(bone, lungs, liver) at the same time and is now under-
going chemotherapy.
Overall best response rate (CR and PR) in patients
undergoing re-RT or RT for macroscopic/residual dis-
ease is 78.3% (47/60 patients, SD in 15/60 pts). To date,
there were 8 complete remissions, one already at the
first follow-up (table 4). In the patient group with
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Re-irradiation visible residual tumor R1/Pn+ resected tumors
patient number 16 60 43
prior surgery 5 26 43
visible residual/no prior surgery 15 60 0
R1/Pn+ 1 0 43
recurrent tumors 16 26 9
re-irradiation 16 15 1
Stages (TNM 7th edition 2010)
T1 1 8
T2 2 7
T3 4 10 7
T4 12 45 15
Tx 1 6
Not applicable 1
N0
N1 1
N2a 2
N2b 1 3 4
N2c 1 1
histology
adenoid cystic carcinoma 13 52 38
mucoepidermoid carcinoma 1 2 3
acinic cell carcinoma 1 3
adenocarcinoma 1 1
squamous cell carcinoma 1 1 1
MSGT NOS 1
site
base of skull 6 9 1
intracranial extension 2
orbit 1 4
orbit/pterygopalatine fossa 4 2 1
petrous bone 1
nasal cavity 1 1
paranasal sinus 3 16 7
maxilla 1 2
palate 1 6
planum buccale 1
nasopharynx 3
oropharynx 1
external auditory canal 1 2
parotid gland 1 12 17
submandibular gland 2 5
sublingual gland 2
base of tongue 2
lacrimal gland 1
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developed an in-field recurrence after initial partial
response (2 patients receiving re-irradiation, 1 patient
receiving primary RT). Both of these patients were re-
treated only 19 and 16 months with 51 GyE and 36.2
GyE for acinic cell and mucoepidermoid carcinoma.
One patient developed an out-of-field recurrence follow-
ing re-irradiation, three patients had distant disease
progressions.
Figures 1, 2, and 3 show a 27 year-old lady with large,
partially-resected ACC (CTV1: 238.6 ml, CTV2: 572.2
ml) before (Figure 1) and 6 months after radiotherapy
(Figure 3) together with the corresponding carbon ion
dose distribution created by a 3-field IMPT (Figure 2).
Discussion
Treatment was generally tolerated well and without
unexpected acute toxicity. Transient alteration of taste,
mild xerostomia, and dysphagia were most frequently
reported. There was no grade IV or V acute toxicity.
These findings are supported by other series using parti-
cle radiation [9,11,14].
Despite the sometimes large treatment volumes, we
have seen only 6 patients with °III dysphagia (5.8%).
Mucositis rates are higher than in our initial or the
Japanese series, however, these mostly included tumors
located at the base of skull [9,15] and smaller target
volumes [11]. Both cohorts [9,11] also did not include
R1-resected tumors. In view of treated sites in our
patient cohort, occurrence of °III mucositis at roughly
10% is still very low especially considering the fact that
the former parotid area was included in 14 out of 40
pts. Also, toxicity does not seem to be increased in the
patients without macroscopic residues.
As especially ACCs tend to show perineural infiltra-
tion, an independent predictor of local control [4-6],
therefore potentially involved neural tracts up to their
entrance into the skull base need to be included as pro-
posed by Garden et al [6]. Consequently, this brings
higher dose close to the middle ear, therefore, the
occurrence of middle ear effusions is not surprising. In
all cases, these symptoms completely resolved at first
follow-up and are therefore acceptable.
Although it is too early to assess treatment efficacy,
response rates and extent of response in the patients
with initially macroscopic residues are promising. With
our updated results showing no difference in local con-
trol between partially resected or primarily irradiated
Table 2 treatment characteristics
re-irradiation range primary irradiation range
patient number 16 87
median dose (GyE/Gy)
C12 44.7 23.9 17.4 - 24.4
IMRT 48.8 49.3 47 - 56.3
total dose 44.9 36.2 - 72.7 73.2 69.9 - 75.3
C12
IMPT 5 17
SBO 10 70
# of fractions 15 8 - 20 8 6 - 8
IMRT
step& shoot IMRT 1 81
Tomotherapy 0 6
treatment volumes (ml)
CTV1 55.2 9.2 - 178.7 128.6 32.6 - 468.6
CTV2 221.2 108.6 - 333.8 368.0 100.2 - 1246.8
prior RT
prior C12-irradiation 6 pts
median prior dose (GyE/Gy) 70 50 - 72
median re-RT dose (GyE/Gy) 44.9 36.2 - 72.7
median cumulative dose (GyE/Gy) 113 59 - 133
time interval (months) 66 16 - 266
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the treatment of MSGT hence needs to be reconsidered.
With rapidly resolving treatment-related side-effects and
very mild late effects [9], the application of extensive
and very often mutilating surgical procedures needs to
be questioned, especially since inclusion of surgical
intervention pathways lead to larger target volumes.
Albeit longer follow-up is needed to assess late
effects of re-irradiation with carbon ions, our patients
did not experience any major acute radiation-induced
toxicity. Observed side-effects were mild, with very fast
responses (i.e. resolution of ocular ptosis) occurring
even under therapy. It has been shown in various pub-
lications that re-irradiation can lead to long-term local
control at least in a subset of patients [20-22]. How-
ever this is bought at the price of increased late effects
with the second course of irradiation. Local control for
the second course of irradiation is challenging and also
dose-dependent, therefore particle therapy appears to
be a logical treatment choice in re-irradiation deliver-
ing high doses to the target while sparing surrounding
normal tissues to a higher extent than either FSRT or
IMRT are able to. While we could - in a small patient
number - show that re-irradiation with carbon ions is
possible maintaining a low (acute) toxicity profile, late
effects still need to be investigated. Two patients in
our re-irradiation cohort developed in-field recurrences
following re-irradiation, therefore further dose escala-
tion may be explored in a controlled clinical trial
setting.
Table 3 acute toxicity at completion of treatment and first follow-up
re-irradiation macroscopic residual microscopic residual
prior to RT end of RT 1st f/u prior to RT end of RT 1st f/u prior to RT end of RT 1st f/u
mucositis I4 1 4 0 1 6 1
II 1 21 1 18 0
III 0 5 0 4 0
dermatitis I2 3 3 1 2 7 0
II 2 10 0 11 0
I I I 01 00
epitheliolyses yes 0 8 0 12
xerostomia I 3 19 19 21 22
II 1 0 0
dysphagia I 0 1 11 6 10 5
I I 60 43
III 4 0 2
weight loss yes 1 24 4 19 5
kg median 4 4 5
min 2 2
max 11 10
feeding tube 03 4 4 4 5
loss of taste 23 7 3 3
middle ear effusion 2 1 11 2 8 2
otitis 146
paralysis of facial nerve 22 55 5 1 0 1 0 9
ptosis 32 31 1
reduced jaw opening 22 88 3 1 2 1 2 5
xerophthalmia 11 11 1
conjunctivitis 10 60 20
lymph edema 22
Table 4 initial treatment response
re-RT primary/R2
(N = 16) (N = 60)
CR 8
PR 93 0
SD 41 1
dna 1 0
pending 2 9
lost to f/u 0 2
CR: complete response
PR: partial response
SD: stable disease
dna: does not apply
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increased heavy-ion part in the treatment regimen will
lead to further improved control rates, none of the local
treatment regimen has yet had an impact on overall sur-
vival or distant metastasis-free survival in MSGT
[2,6,7,9]. The use of concomitant chemotherapy or
immunotherapy in squamous cell carcinoma of the head
and neck [23,24] has led to a significant improvement
not only in local control but also in overall survival.
Radiochemotherapy in treatment of MSGT however, has
not evolved beyond the phase II-stage or retrospective
analysis of very heterogeneous treatment regimen
[25-27] so far.
Hence two open questions still remain: can we
increase local control at acceptable rates of side-effects
in adenoid cystic carcinoma and other malignant sali-
vary gland tumors by increase of the carbon ion RT
part? A prospective controlled trial is currently under
way to address this issue [17]. The other question is
whether patients with adenoid cystic carcinoma will
profit from combined treatment with i.e. new substances
such as EGFR-inhibitors, which will potentially not
Figure 1 extensive adenoid cystic carcinoma in 27 year-old lady prior to RT.
Figure 2 corresponding carbon ion dose distribution by a 3-field IMPT: 100% corresponding to 24 GyE.
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[23,28] in terms of local and distant control. This issue
will also shortly be addressed in a prospective phase-II
trial [29].
Conclusion
Achieving local control in MSGT remains challenging.
IMRT with carbon ion boost has led to only mild acute
side effects in R2-resected tumors of the skull base, toxi-
city does not seem to be increased in R1-resected
tumors of this series. R2-resected patients showed pro-
mising treatment response, follow-up is yet too short
though to assess long-term local control and potential
late effects. Carbon ion therapy for re-irradiation has
been shown to be feasible and without significant asso-
ciated acute toxicity.
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